Clinical trial results are critical for medical device companies like Axogen. Positive outcomes, such as meeting the primary endpoint in a post-marketing study, typically result in increased investor confidence and can lead to a rise in stock price. The success of AxoGuard Nerve Cap in reducing pain is a significant milestone that may enhance the product's marketability and drive revenue growth.